Abstract
Since 2014, a series of clinical trials involving new therapeutic approaches to reduce residual risk in patients with chronic coronary disease (CCD) have been published, demonstrating a significant reduction in cardiovascular events in this population. These therapies involve medications to control LDL-cholesterol, such as PCSK-9 inhibitors, medications for glycemic control such as GLP-1 …